IgA Nephropathy (IgAN) has varied clinical presentations from asymptomatic microscopic hematuria to rapidly progressive crescentic glomerulonephritis. Almost 30% of patients ultimately progress to ESKD within 20 years. Geographical variability in long-term outcome of IgAN is partly explained by lead-time bias and inclusion of milder cases in centers with good outcomes. Conservative treatment has proven to be very effective in IgAN, as shown in STOP-IgAN trial , where almost one third of patients who completed intensive optimization of conservative therapy over 6 months period, no longer qualified for randomization to the immunosuppressive therapy arm of the trial.
Shares Share On Facebook Tweet Share Email Share Share Pin It Share Comment Buff actors fighting for major Hollywood roles isn’t breaking news, but how they got those bulging biceps and 6-packs makes for a good tale. Steroid abuse has been around for decades, impacting sports and the big screen in plenty of not-so-positive ways. With technology advancing in the muscle enhancement drug industry, it’s become difficult to determine who’s using ─ and who’s not.
[ Editor's Note: Chryste Gaines, MBA, Olympic gold and bronze medal sprinter and former teammate of Marion Jones in the 2000 Sydney Olympic Games, stated the following in a Dec. 22, 2008 email to in response to the IOC ruling:
"We are being unfairly punished. If the drug testing agencies cannot determine if an athlete is taking performance enhancing drugs how are the teammates supposed to know?... It negates all the family functions, church functions, and social events we missed in the name of winning an Olympic medal." ]